virtual CROI 2021 Schedule at a Glance Version 3 (Short) LIVE PROGRAM TIME SATURDAY, MARCH 6, 2021 SUNDAY, MARCH 7, 2021 10:00 AM W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES OPENING SESSION (10:00 – 12:05) EST (10:00 – 14:00) CHAIRS WELCOME TO virtual CROI 2021 START Conveners: Serena S. Spudich and Nicolas Chomont Chairs: Sharon L. Hillier, James A. Hoxie, and Elaine J. Abrams ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 MARTIN DELANEY PRESENTATION LIVE PROGRAM Frank Kirchhoff INTRODUCTION ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY James Pickett Galit Alter VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-CoV-2 VACCINES WILL PERPETUATE THE PANDEMIC ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC Gregg S. Gonsalves and Fatima Hassan Jürgen Rockstroh BERNARD FIELDS LECTURE ADVANCES IN BIOMEDICAL PREVENTION OF HIV INTRODUCTION Jean-Michel Molina James A. Hoxie and Galit Alter ADVANCES IN HIV CURE NEUTRALIZING ANTIBODIES AGAINST CORONAVIRUSES Katherine J. Bar Pamela J. Bjorkman N'GALY-MANN LECTURE INTRODUCTION Elaine J. Abrams and Tedros Adhanom Ghebreyesus LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET Anthony S. Fauci 12:20 PM CONCURRENT WORKSHOPS (12:20 – 2:20) EST W-2 FRONTIERS IN LABORATORY TECHNOLOGIES Conveners: Galit Alter and Frank Kirchhoff STRUCTURES OF SARS-CoV-2 ANTIBODIES INDUCED BY INFECTION AND mRNA VACCINES Christopher O. Barnes EMERGING CONCEPTS IN HIV-1 RESTRICTION Edward Campbell SARS-CoV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES Daniela Weiskopf ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING Sai Reddy W-3 CLINICAL TRIAL DESIGN AND ANALYSIS Conveners: Susan P. Buchbinder and Richard E. Chaisson MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS Lori Dodd DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS Holly Janes W-4 CASE TRACING AND CASE MANAGEMENT: COVID-19 WORKSHOP Conveners: Robert T. Schooley and David L. Thomas RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19 Kwok-Yung Yuen COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS Sanjay Bhagani CRITICAL CARE OF COVID-19 Janhavi Athale LIVE PROGRAM Last Updated on March 4, 2021 LIVE PROGRAM TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2021 WEDNESDAY, MARCH 10, 2021 10:00 PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) AM EST Session Hosts: Wesley Sundquist and Carlos del Rio Session Hosts: Peter W. Hunt and Sharon L. Hillier Session Hosts: Nicolas Chomont and Elaine J. Abrams START WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP Sharon L. Hillier Elaine J. Abrams James A. Hoxie P-1 IMAGING VIRAL LIFE CYCLES P-3 HIV-1 bNAbs: LOOKING AHEAD P-5 ELITE CONTROLLERS: A MODEL FOR A FUNCTIONAL CURE OF HIV-1 INFECTION Hans-Georg Kräusslich Marina Caskey Xu Yu P-2 DISPARITIES IN HEALTH: FROM HIV TO COVID-19 AND BEYOND P-4 SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV P-6 HIV TREATMENT IN PREGNANCY: BEYOND PREVENTION OF VERTICAL TRANSMISSION James E. Hildreth Linda-Gail Beker Shahin Lockman LIVE PROGRAM 11:15 AM CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) EST O-1 HIV/SIV HOST AND CELLULAR INTERCTIONS: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-5 SARS-CoV-2 VS HOST: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-10 HIV RESERVOIRS Oral Abstract Moderators: John M. Coffin and Richard A. Koup Oral Abstract Moderators: Wesley I. Sundquist and Guido Silvestri Oral Abstract Moderators: Douglas D. Richman and Katharine J. Bar DECIPHERING THE HOST NUCLEUS SUBVERSION BY HIV-1 TO REPLICATE IFITM PROTEINS PROMOTE SARS-CoV-2 INFECTION IN HUMAN LUNG CELLS INFECTED CELLS ARE CLONOTYPICALLY DIVERSE IN BLOOD & LYMPH NODES SINCE FIEBIG STAGE I Francesca Di Nunzio Caterina Prelli Bozzo Pierre Gantner HIV-1 CAPSID RETAINS ITS INTEGRITY UNTIL MINUTES BEFORE UNCOATING IN THE NUCLEUS SARBECOVIRUS ORF6 PROTEINS ANTAGONIZE INTERFERON SIGNALING EVOLUTIONARY DYNAMICS OF HIV RESERVOIR CELLS VIA A NOVEL SINGLE-CELL MULTIOMICS ASSAY Chenglei Li Izumi Kimura Kevin B. Einkauf TRAFFICKING OF HIV-1 ENVELOPE TO THE EHD1/MICAL-L1 TUBULAR-SORTING ENDOSOME SEVERE COVID-19 IS FUELED BY DISRUPTED GUT BARRIER INTEGRITY NONINVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POSTTREATMENT HIV CONTROL Paul Spearman Leila B. Giron Leila B. Giron A COMPREHENSIVE CRISPR SCREEN FOR HIV DEPENDENCY FACTORS SARS-CoV-2 PERSISTS IN INTESTINAL ENTEROCYTES UP TO 7 MONTHS AFTER SYMPTOM RESOLUTION PD-1 BLOCKADE ENHANCES THERAPEUTIC BENEFITS OF VACCINE IN A CHRONIC SIV/MACAQUE MODEL Vanessa R. Montoya Minami Tokuyama Sheikh A. Rahman EARLY bNAb THERAPY IN SHIVAD8-EO–INFECTED RHESUS MACAQUES COVID-19 OUTCOME: INSIGHTS FROM QUANTIFICATION OF VIREMIA AND NEUTRALIZING ANTIBODY TYPE I INTERFERON-ASSOCIATED GENE EXPRESSION PREDICTS TIME TO VIRAL REBOUND ON TI Joana Dias Penny Zacharopoulou IMMUNE CORRELATES OF POSTTREATMENT CONTROL IN SHIV-INFECTED INFANT MACAQUES Jana L. Jacobs Veronica Obregon-Perko CHARACTERIZATION AND EPITOPE MAPPING OF SARS-CoV-2–SPECIFIC T CELLS HIV-1 PROVIRUS CANNOT BE REACTIVATED IN PATIENTS ON TREATMENT WITH ART AND DASATINIB SIV∆GY INFECTION INDUCES ELITE CONTROL AND RESISTANCE TO SHIV HETEROLOGOUS CHALLENGE Kristin L. Boswell Mayte Coiras Susan Pereira Ribeiro BARICITINIB LOWERS INFLAMMATION AND PATHOLOGY IN SARS-CoV-2–INFECTED RHESUS MACAQUES DURABLE HIV-1 ANTIBODY PRODUCTION IN HUMANS AFTER AAV8-MEDIATED GENE TRANSFER TRAPPING THE HIV-1 V3 LOOP IN A HELICAL CONFORMATION ENABLES BROAD NEUTRALIZATION Timothy Hoang Joseph P. Casazza Matthias Glögl ONE DOSE OF COVID-19 mRNA VACCINE IN SARS-CoV-2–EXPERIENCED PEOPLE MAY BE SUFFICIENT A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION AN Env-gag mRNA VACCINE PROTECTS MACAQUES FROM HETEROLOGOUS TIER-2 SHIV INFECTION Mark Mulligan Beatriz Mothe Peng Zhang SARS-CoV-2 RECRUITS A HAEM METABOLITE TO EVADE ANTIBODY IMMUNITY O-11 BRAIN CONNECTIONS, MALIGNANCIES, AND TUMOR VIRUSES O-2 HIV TREATMENT AND PREVENTION: NEW OPPORTUNITIES TO OPTIMIZE DRUG DOSING, ADHERENCE, AND Annachiara Rosa Oral Abstract Moderators: Dennis L. Kolson and Ronald T. Mitsuyasu ANTIRETROVIRAL THERAPY O-6 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART Oral Abstract Moderators: Angela Kashuba and Courtney V. Fletcher Oral Abstract Moderators: Kazuo Suzuki ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP Joseph J. Eron and Douglas D. Richman 3T BRAIN MRS REVEALS DISTINCT METABOLITE PATTERNS OF ART INITIATION DURING ACUTE HIV Munjal Patel BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING Napapon Sailasuta NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS Myron S. Cohen EFFECTS OF HIV AND AGING ON FUNCTIONAL CONNECTIVITY AND ANATOMY Randolph P. Matthews BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS Patrick H. Luckett CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS Michael Dougan DIVERGENT AND SELF-REACTIVE IMMUNE RESPONSES IN THE CNS OF COVID-19 PATIENTS Justin Lutz CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS Shelli F. Farhadian PK AND SAFETY OF HIGH-DOSE RIFAMPICIN IN TB/HIV COINFECTED PATIENTS ON EFV OR DTG Meagan P. O'Brien CHROMOSOMAL COPY NUMBER ALTERATIONS IN ANAL PRECANCERS FROM PEOPLE WITH HIV Christine Sekaggya-Wiltshire POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL Tinaye Mutetwa PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH EFV-BASED ART IN ACTG 5375 Carlijn Jordans POMALIDOMIDE AND LIPOSOMAL DOXORUBICIN FOR KAPOSI SARCOMA +/– OTHER KSHV DISEASES Kimberly K. Scarsi ESTIMATING WITHIN-HOST R0 FOR SARS-CoV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY Ramya Ramaswami EMTRICITABINE TRIPHOSPHATE IN DRIED BLOOD SPOTS PREDICTS FUTURE VIREMIA IN PWH Ruian Ke VAGINAL pH PREDICTS CERVICAL INTRAEPITHELIAL NEOPLASIA-2 REGRESSION IN HIV+ WOMEN Jose R. Castillo-Mancilla PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 Katherine G. Michel TENOFOVIR DIPHOSPHATE TO PREDICT FUTURE VIRAEMIA IN POSTPARTUM WOMEN LIVING WITH HIV Christoph Spinner WILMS' TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13 Jasantha Odayar POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH Ayana Morales NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: 48WKS PRIMARY OUTCOME Sorana Segal-Maurer INFLAMMASOME ACTIVATION IN PATIENTS WITH KSHV-ASSOCIATED DISORDERS Nicholas Paton ACTIVITY AND RESISTANCE HARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR Ramya Ramaswami RANDOMIZED TRIAL OF RESISTANCE TESTING FOR VIROLOGIC FAILURE IN SUB-SAHARAN AFRICA Laurie VanderVeen O-12 MATERNAL AND CHILD HIV AND SARS-CoV-2 Mark Siedner RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT Oral Abstract Moderators: Landon Myer and Hermione Lyall O-3 COMPLICATIONS OF HIV AND COVID-19 Tracy L. Diamond COVID-19 INFECTION IN HIGH-RISK SOUTH AFRICAN PREGNANCIES WITH AND WITHOUT HIV Oral Abstract Moderators: Judith S. Currier and Peter W. Hunt O-7 TUBERCULOSIS AND HEPATITIS Liesl De Waard SHORT-COURSE ALENDRONATE FOR THE PREVENTION OF ART-ASSOCIATED BONE LOSS Oral